Purple Ventures’ Post

#ICYMI...Calling all KOL's, Analysts, Patient Advocates and Investors who share a common interest in #neurodegenerativediseases. Please join us for our R&D update next Thursday. "Beyond Symptomatic Treatment of #Parkinson’s Disease: Gain Therapeutics R&D Update with KOL & Analyst Insights 2024" Date: February 22nd, 2024 Time: 11:00 am - 12:00 pm EST Register for the Event here: https://lnkd.in/erx-c4vn Send any questions you’d like answered in our Q&A to ir@gaintherapeutics.com. Discussion Topics GBA-associated Parkinson’s Disease & other Synucleinopathies: current unmet medical needs and needed therapies. From biology to classification: understanding Parkinson’s Disease. Discussion of recent in vivo data for GT-02287 as a best-in-class small molecule, for the treatment of GBA-Parkinson’s Disease and other neurodegenerative diseases. Speakers Gain Therapeutics Matthias Alder - Chief Executive Officer Joanne Taylor – Senior Vice President, Research Key Opinion Leaders Professor Roy Alcalay Prof. Alcalay is Chief of the Movement Disorders Division at Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. He also holds an associate professorship in clinical neurology at Columbia University. His research focuses on biomarkers and genetics in Parkinson’s Disease. He is a member of The Michael J. Fox Foundation for Parkinson's Research-funded Parkinson’s Progression Markers Initiative (PPMI) executive steering committee, and the PI of the Parkinson’s Foundation-funded PD GENEration study. Professor Tiago Fleming Outeiro Prof. Outeiro is Professor and Director of the Department of Experimental Neurodegeneration at the University Medical Center Göttingen in Germany. He is also Professor at Newcastle University. His research interests are focused on the understanding of the molecular mechanisms of neurodegenerative diseases such as Parkinson’s, Huntington’s, and Alzheimer’s disease. He is Chair of the Task Force on the Biological Definition of Parkinson’s Disease of Internation Parkinson and Movement Disorder Society.

Revolutionizing Parkinson's Disease Detection and Treatment: The Role of Alpha-Synuclein Fibrils #parkinsonsdisease https://lnkd.in/eiDAu8xZ

⚡ Cell-type-specific Alzheimer’s disease polygenic risk scores are associated with distinct disease processes in Alzheimer’s disease | Nature Discover more at "voltsbase.com/energy" #Energy #Voltsbase

September is National Sickle Cell Awareness Month, designated by Congress to help focus attention on the need for research and treatment of sickle cell disease. During National Sickle Cell Awareness Month, we recognize the perseverance and strength of the community of people living with this disease and recommit to developing more effective treatments. Approximately 100,000 Americans have Sickle Cell Disease (SCD) — a group of inherited red blood cell disorders that can cause acute, chronic pain and serious health complications, including infections, strokes, organ damage, vision problems, and serious fatigue. Living with SCD often means putting the goals and plans of everyday life on hold to accommodate the demands of the disease, enduring frequent unplanned hospital stays... #SickleCellAwareness #HealthEquity #CureSickleCell

𝗘𝘅𝗽𝗹𝗼𝗿𝗶𝗻𝗴 𝗠𝗮𝗿𝗸𝗲𝘁 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀: Netherton Syndrome Curious about the latest advancements in the field of Netherton Syndrome? Look no further! Wissen Research brings you an in-depth report that sheds light on every aspect of this disease, highlighting: #MarketInsights #ProductAnalysis #CompetitiveAnalysis #PatentAnalysis #ClinicalTrials #Treatment #OpportunityAnalysis #MarketForecast – 2023-2033 For detailed report: https://lnkd.in/dXBAxyKx Request customized report: https://lnkd.in/d6q8Q-5a #marketresearch #marketreport #marketforecast #askforcustomization #wissenresearch #marketinsight #MarketReport2023 #MarketReport2033 #NethertonSyndrome

𝗘𝘅𝗽𝗹𝗼𝗿𝗶𝗻𝗴 𝗠𝗮𝗿𝗸𝗲𝘁 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀: Hepatorenal syndrome Curious about the latest advancements in the field of Hepatorenal syndrome? Look no further! Wissen Research brings you an in-depth report that sheds light on every aspect of this disease, highlighting: #MarketInsights #ProductAnalysis #CompetitiveAnalysis #PatentAnalysis #ClinicalTrials #Treatment #OpportunityAnalysis #marketforecast For detailed report: https://lnkd.in/gBkwq2np Request customized report: https://lnkd.in/d6q8Q-5a #marketresearch #marketreport #marketforecast #askforcustomization #wissenresearch #marketinsights #HepatorenalSyndrome

The analysis of data from a historic cohort of 545 systemic sclerosis patients uncovers links between autoantibodies and interstitial lung disease HRCT patterns: *️⃣ Lymphoid interstitial pneumonia ➡️ Anti-U1 snRNP *️⃣ Organizing Pneumonia ➡️ Anti PM/Scl *️⃣ Non-specific interstitial pneumonia ➡️ Anti-Scl70

Alzheimer's disease is a cruel condition. it can be diagnosed early however, but that requires an invasive lumbar puncture. A new finding shows that in the near future, a simple blood test may be able to detect this disease very early, allowing treatment to be more effective. Take a look at the article below to learn more. Call us if you are needing in-home care for your loved one. #dementiaawareness #alzheimersawareness #inhomecare #baltimorecounty

Embrace the Light in the Fight Against #MitochondrialDisease! Our experts are tirelessly working to decode the secrets of #mitochondrial dysfunction and its connection to mitochondrial disease. Together, we're dedicated to transforming this knowledge into treatments that can brighten the lives of our patients. 🧡 Learn more about mitochondrial disease and the groundbreaking #research happening at the 🙌: https://loom.ly/0-GDrro

In this exclusive Q&A session with Dr. Andras Kapus, we unravel the complexities of chronic kidney disease in general and #PolycysticKidneyDisease (#PKD) in particular, and delve into the ongoing research efforts aimed at combatting #KidneyFibrosis https://bit.ly/3FAF24Q